Assessment of the effect of mefloquine on artesunate pharmacokinetics in healthy male volunteers

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 3, 2007, Pages 1099-1101

  Davis, Timothy M E ^a   England, Michelle ^a   Dunlop, Anne Marie ^a   Page Sharp, Madhu ^a   Cambon, Nathalie ^b   Keller, Thomas G ^b   Heidecker, János L ^b   Ilett, Kenneth F ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Mepha Ltd   (Switzerland)

^c PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; DIHYDROARTEMISININ; DRUG METABOLITE; MEFLOQUINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; NEUROLOGIC DISEASE; NORMAL HUMAN; PRIORITY JOURNAL; VIVID DREAM;

ADULT; ANTIMALARIALS; AREA UNDER CURVE; ARTEMISININS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; HUMANS; MALE; MEFLOQUINE; MIDDLE AGED; SESQUITERPENES; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 33847653766     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01253-06     Document Type: Article

References (19)

1. Ashley, E. A., K. Stepniewska, N. Lindegardh, R. McGready, R. Hutagalung, R. Hae, P. Singhasivanon, N. J. White, and F. Nosten. 2006. Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 50:2281-2285.
2. Ashley, E. A., and N. J. White. 2005. Artemisinin-based combinations. Curr. Opin. Infect. Dis. 18:531-536.
3. Ashton, M., T. N. Hai, N. D. Sy, D. X. Huong, N. Van Huong, N. T. Nieu, and L. D. Cong. 1998. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab. Dispos. 26:25-27.
4. Ashton, M., D. S. Nguyen, V. H. Nguyen, T. Gordi, N. H. Trinh, X. H. Dinh, T. N. Nguyen, and D. C. Le. 1998. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin. Pharmacol. Ther. 63:482-493.
5. Batty, K. T., K. F. Ilett, S. M. Powell, J. Martin, and T. M. E. Davis. 2002. Relative bioavailability of artesunate and dihydroartemisinin: investigations in the isolated perfused rat liver and in healthy Caucasian volunteers. Am. J. Trop. Med. Hyg. 66:130-136.
6. Boudreau, E. F., L. Fleckenstein, L. W. Pang, G. E. Childs, A. C. Schroeder, B. Ratnaratorn, and P. Phintuyothin. 1990. Mefloquine kinetics in cured and recrudescent patients with acute falciparum malaria and in healthy volunteers. Clin. Pharmacol. Ther. 48:399-409.
7. Burk, O., K. A. Arnold, A. K. Nussler, E. Schaeffeler, E. Etimova, B. A. Avery, M. A. Avery, M. F. Fromm, and M. Eichelbaum. 2005. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol. Pharmacol. 67:1954-1965.
8. Davis, T. M. E., K. T. Batty, K. F. Ilett, N. C. Hung, S. M. Powell, H. V. Thien, and T. Q. Binh. 2001. Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria. Antimicrob. Agents Chemother. 45:181-186.
9. Davis, T. M. E., H. A. Karunajeewa, and K. F. Ilett. 2005. Artemisinin-based combination therapies for uncomplicated malaria. Med. J. Aust. 182:181-185.
10. Desjardins, R. E., C. L. Pamplin, J. von Bredow, K. G. Barry, and C. J. Canfield. 1979. Kinetics of a new antimalarial, mefloquine. Clin. Pharmacol. Ther. 26:372-379.
11. Giao, P. T., and P. J. de Vries. 2001. Pharmacokinetic interactions of antimalarial agents. Clin. Pharmacokinet. 40:343-373.
12. Karbwang, J., K. Na Bangchang, A. Thanavibul, D. J. Back, D. Bunnag, and T. Harinasuta. 1994. Pharmacokinetics of mefloquine alone or in combination with artesunate. Bull. W. H. O. 72:83-87.
13. Na-Bangchang, K., A. Thanavibul, P. Tippawangkosol, and J. Karbwang. 2005. Pharmacokinetics of the four combination regimens of dihydroartemisinin/mefloquine in acute uncomplicated falciparum malaria. Southeast Asian J. Trop. Med. Public Health 36:23-33.
14. Na-Bangchang, K., P. Tippanangkosol, R. Ubalee, S. Chaovanakawee, S. Saenglertsilapachai, and J. Karbwang. 1999. Comparative clinical trial of four regimens of dihydroartemisinin-mefloquine in multidrug-resistant falciparum malaria. Trop. Med. Int. Health 4:602-610.
15. Na-Bangchang, K., P. Tippawangkosol, A. Thanavibul, R. Ubalee, and J. Karbwang. 1999. Pharmacokinetic and pharmacodynamic interactions of mefloquine and dihydroartemisinin. Int. J. Clin. Pharmacol. Res. 19:9-17.
16. Price, R., J. A. Simpson, P. Teja-Isavatharm, M. M. Than, C. Luxemburger, D. G. Heppner, T. Chongsuphajaisiddhi, F. Nosten, and N. J. White. 1999. Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. Antimicrob. Agents Chemother. 43:341-346.
17. Simpson, J. A., R. Price, F. ter Kuile, P. Teja-Isavatharm, F. Nosten, T. Chongsuphajaisiddhi, S. Looareesuwan, L. Aarons, and N. J. White. 1999. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin. Pharmacol. Ther. 66:472-484.
18. Thomann, P. 1993. Non-compartmental analysis methods manual, p. 5-66. in G. Heinzel, R. Woloszcak, and P. Thomann (ed.), TopFit 2.0 pharmacokinetic and pharmacodynamic data analysis system for the PC. Gustav Fischer, Stuttgart, Germany.
19. U.S. Food and Drug Administration. 2002. Bioavailability and bioequivalence studies for orally administered drug products-general considerations. U.S. Food and Drug Administration Center for Drug Evaluation and Research, Washington, DC. http://www.fda.gov/cder/guidance/3615fnl.htm. Accessed August 2006.